ClinicalTrials.gg
Active, not recruitingNCT01651403Updated Jan 30, 2026Results posted

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

A Phase 3 interventional study of Tenofovir DF and TDF Placebo in Chronic Hepatitis B, sponsored by Gilead Sciences. Active, not recruiting at 21 sites in 5 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
34th of 50
90 · median 117
Started
2012
with 7 others
Phase 3
13 of 50
none open now
Registered
26th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 34th largest by enrollment, is one of 8 that started in 2012, is one of 13 in phase 3, and was the 26th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to \< 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or Female, 2 to \< 12 years of age
  • Weight ≥ 10 kg
  • Chronic infection ≥ 6 months
  • Hepatitis B e antigen (HBeAg)-positive or HBeAg-negative
  • HBV Viral Load ≥ 100,000 copies/mL
  • (ALT) ≥ 1.5 x the (ULN) at screening
  • ≥ 80 mL/min/1.73m\^2
  • (ANC) ≥ 1,500/mm\^3, ≥ 10 g/dL
  • Negative pregnancy test at screening
  • No prior tenofovir DF therapy (participants may have received prior interferon-alfa and/or other oral anti-HBV nucleoside/nucleotide therapy; participants must have discontinued interferon-alfa therapy ≥ 6 months prior to screening; participants experienced on other anti-HBV nucleoside/nucleotide therapy must have discontinued therapy ≥ 16 weeks prior to screening to avoid flare if randomized to the placebo arm)

Key Exclusion Criteria:

  • Pregnant or lactating
  • Decompensated liver disease
  • Received interferon therapy within 6 months of screening
  • Received anti-HBV nucleoside/nucleotide therapy within 16 weeks of screening
  • Alpha-fetoprotein levels > 50 ng/mL
  • Evidence of hepatocellular carcinoma (HCC)
  • Co-infection with (HIV), acute hepatitis A virus (HAV), virus (HCV), or hepatitis D virus (HDV)
  • Chronic liver disease not due to HBV
  • History of significant renal, cardiovascular, pulmonary, neurological or bone disease
  • Long term non-steroidal, anti-inflammatory drug therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Tenofovir DF (Blinded Randomized Treatment)

    Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).

    Drug: Tenofovir DF

  • Placebo comparator
    Placebo to match TDF (Blinded Randomized Treatment)

    Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).

    Drug: TDF Placebo

  • Experimental
    Tenofovir DF (Open-label Treatment)

    Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).

    Drug: Tenofovir DF

  • Experimental
    Tenofovir DF (Open-label Extension Phase)

    Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.

    Drug: Tenofovir DF

Interventions

  • * Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight). * Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg.

    Also known as: Viread®

  • DrugTDF Placebo

    * Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily. * Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)

    Time frame: Week 48

  2. Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48

    HBeAg seroconversion was defined as HBeAg loss and a change from HBeAb negative or missing at baseline to HBeAb positive.

    Time frame: Week 48

  2. Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.

    Time frame: Week 48

  3. Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.

    Time frame: Week 192

  4. Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.

    Time frame: Week 48

  5. Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.

    Time frame: Week 192

  6. Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 48

  7. Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 192

  8. Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 48

  9. Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 192

  10. Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 48

  11. Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192

    Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 192

  12. Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 48

  13. Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192

    Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

    Time frame: Week 192

  14. Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48

    Time frame: Week 48

  15. Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192

    Time frame: Week 192

  16. Percentage of Participants With HBsAg Loss at Week 48

    HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.

    Time frame: Week 48

  17. Percentage of Participants With HBsAg Loss at Week 192

    HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.

    Time frame: Week 192

  18. Percentage of Participants With HBsAg Seroconversion at Week 48

    HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.

    Time frame: Week 48

  19. Percentage of Participants With HBsAg Seroconversion at Week 192

    HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.

    Time frame: Week 192

  20. Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48

    Time frame: Baseline; Week 48

  21. Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96

    Time frame: Baseline; Week 96

  22. Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144

    Time frame: Baseline; Week 144

  23. Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192

    Time frame: Baseline; Week 192

  24. Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48

    Time frame: Baseline; Week 48

  25. Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192

    Time frame: Baseline; Week 192

  26. Percent Change From Baseline in BMD of Spine at Week 48

    Time frame: Baseline; Week 48

  27. Percent Change From Baseline in BMD of Spine at Week 192

    Time frame: Baseline; Week 192

07

Results

Posted Sep 19, 2018

Participant flow

Participants were enrolled at study sites in the United States, Asia, and Europe.The first participant was screened on 06 December 2012. The last Week 192 study visit occurred on 02 June 2020.

Double-Blind Period (Through Week 48/72)
Participant flow — Double-Blind Period (Through Week 48/72)
MilestoneTenofovir Disoproxil FumaratePlacebo
Started6030
Completed5625
Not completed45
Withdrew: Participant noncompliance11
Withdrew: Withdrew consent/assent33
Withdrew: Randomized but not treated01
Open-Label Phase (Weeks 49/73-192)
Participant flow — Open-Label Phase (Weeks 49/73-192)
MilestoneTenofovir Disoproxil FumaratePlacebo
Started5625
Completed3511
Not completed2114
Withdrew: Continuing study139
Withdrew: Investigator decision21
Withdrew: Withdrew consent/assent64

Outcome measures

PrimaryPercentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Failure Approach)76.7 (64.0 to 86.6)6.9 (0.8 to 22.8)
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = < 0.0012-sided Cochran-Mantel-Haenszel test adjusted for age at baseline and region strata
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Fisher Exact · p = < 0.001Fisher's exact test without adjusting for strata at baseline
SecondaryPercentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48

HBeAg seroconversion was defined as HBeAg loss and a change from HBeAb negative or missing at baseline to HBeAb positive.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 4825.024.1
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = 0.9352-sided Cochran-Mantel-Haenszel test adjusted for age at baseline and region strata
SecondaryPercentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Normal Alanine Aminotransferase (ALT) at Week 48, Based on the American Association for the Study of Liver Diseases (AASLD) Normal Range51.717.2
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = 0.0012-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryPercentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With Normal ALT at Week 192, Based on the AASLD Normal Range71.751.7
SecondaryPercentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Normal ALT at Week 48, Based on the Central Lab Normal Range65.017.2
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.0012-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryPercentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With Normal ALT at Week 192, Based on the Central Lab Normal Range80.062.1
SecondaryPercentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Normalized ALT at Week 48, Based on the AASLD Normal Range51.717.9
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = 0.0022-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryPercentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With Normalized ALT at Week 192, Based on the AASLD Normal Range71.750.0
SecondaryPercentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Normalized ALT at Week 48, Based on the Central Lab Normal Range65.514.8
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.0012-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryPercentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With Normalized ALT at Week 192, Based on the Central Lab Normal Range79.359.3
SecondaryComposite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 4846.77.1
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.0012-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryComposite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192

Normal ALT was defined as ≤ 30 U/L for males and females 0-12 years based on the AASLD pediatric normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on AASLD Normal Range) at Week 19270.042.9
SecondaryComposite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 4853.47.4
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.0012-sided Cochran-Mantel-Haenszel tests adjusted for age at baseline and region strata
SecondaryComposite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192

Normal ALT was defined as ≤ 34 U/L for females aged 2-15 years old or males aged 1-9 years old, and ≤ 43 U/L for males aged 10-15 years old based on the central lab normal range. ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Composite Endpoint of Percentage of Participants With HBV DNA < 400 Copies/mL (69 IU/mL) and Normalized ALT (Based on Central Lab Normal Range) at Week 19275.955.6
SecondaryPercentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 4871.76.9
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.001two-sided Cochran-Mantel-Haenszel test adjusted for age at baseline and region strata
SecondaryPercentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192
Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With HBV DNA < 169 Copies/mL (29 IU/mL) at Week 19281.762.1
SecondaryPercentage of Participants With HBsAg Loss at Week 48

HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With HBsAg Loss at Week 483.33.4
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = >0.999Two-sided Cochran-Mantel-Haenszel test adjusted for age at baseline and region strata
SecondaryPercentage of Participants With HBsAg Loss at Week 192

HBsAg Loss was defined as a change from HBsAg positive or missing at baseline to HBsAg negative.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With HBsAg Loss at Week 19210.00
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 48

HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With HBsAg Seroconversion at Week 4800
SecondaryPercentage of Participants With HBsAg Seroconversion at Week 192

HBsAg seroconversion was defined as HBsAg loss and a change from HBsAb negative or missing at baseline to HBsAb positive.

Time frame:
Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With HBsAg Seroconversion at Week 19200
SecondaryNumber of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48
Time frame:
Baseline; Week 48
Reported as:
Count of participants · Participants
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 48
ParticipantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 4857
SecondaryNumber of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96
Time frame:
Baseline; Week 96
Reported as:
Count of participants · Participants
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 96
ParticipantsTDF to TDFPlacebo to TDF
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 9612
SecondaryNumber of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144
Time frame:
Baseline; Week 144
Reported as:
Count of participants · Participants
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 144
ParticipantsTDF to TDFPlacebo to TDF
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 14410
SecondaryNumber of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192
Time frame:
Baseline; Week 192
Reported as:
Count of participants · Participants
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 192
ParticipantsTDF to TDFPlacebo to TDF
Number of Participants With Sequence Changes From Baseline Within the HBV Polymerase for Participants Who Were Viremic (HBV DNA ≥ 400 Copies/mL [69 IU/mL]) Including Participants With Confirmed Virologic Breakthrough at Week 19200
SecondaryPercentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48
Time frame:
Baseline; Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 48
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine Bone Mineral Density (BMD) at Week 4818.36.9
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Exact chan-zhang method: 11.4 · 95% CI -6.9 to 25.1
SecondaryPercentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192
Time frame:
Baseline; Week 192
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 192
percentage of participantsTDF to TDFPlacebo to TDF
Percentage of Participants With ≥ 4% Decrease From Baseline in Spine BMD at Week 19218.36.9
Statistical analysis
  • TDF to TDF vs Placebo to TDF · Exact chan-zhang method: 11.4 · 95% CI -6.9 to 25.1
SecondaryPercent Change From Baseline in BMD of Spine at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · Percent change in spine BMD
Percent Change From Baseline in BMD of Spine at Week 48
Percent change in spine BMDTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percent Change From Baseline in BMD of Spine at Week 483.798 ± 5.91187.557 ± 4.9790
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · ANOVA · p = 0.007two-sided superiority test
SecondaryPercent Change From Baseline in BMD of Spine at Week 192
Time frame:
Baseline; Week 192
Reported as:
Mean · Percent change in spine BMD
Percent Change From Baseline in BMD of Spine at Week 192
Percent change in spine BMDTDF to TDFPlacebo to TDF
Percent Change From Baseline in BMD of Spine at Week 19219.168 ± 12.280526.085 ± 14.2586
PrimaryPercentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)
percentage of participantsTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)
Percentage of Participants With Serum HBV DNA < 400 Copies/mL (69 IU/mL) at Week 48 (Missing = Excluded Approach)83.6 (71.2 to 92.2)7.7 (0.9 to 25.1)
Statistical analysis
  • TDF (Blinded Randomized Phase) vs Placebo (Blinded Randomized Phase) · Cochran-Mantel-Haenszel · p = <0.0012-sided Cochran-Mantel-Haenszel test adjusted for age at baseline and region strata

Adverse events

Collected over First dose date up to the Week 192 Data Cut for Open-Label Phase; Additional adverse event data will be reported after study is completed and final analysis is done.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TDF (Blinded Randomized Phase)0/60 (0%)10/60 (16.7%)38/60 (63.3%)
Placebo (Blinded Randomized Phase)0/30 (0%)2/29 (6.9%)16/29 (55.2%)
TDF to TDF (Open-Label Phase)0/56 (0%)8/56 (14.3%)21/56 (37.5%)
Placebo to TDF (Open-Label Phase)0/25 (0%)3/25 (12%)7/25 (28%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)TDF to TDF (Open-Label Phase)Placebo to TDF (Open-Label Phase)
Alanine aminotransferase increasedInvestigations4/601/291/560/25
AppendicitisInfections and infestations0/600/290/561/25
BronchitisInfections and infestations0/600/290/561/25
Hand-foot-and-mouth diseaseInfections and infestations0/600/290/561/25
PharyngitisInfections and infestations0/600/291/561/25
DehydrationMetabolism and nutrition disorders0/600/291/561/25
HypoglycaemiaMetabolism and nutrition disorders0/601/290/560/25
Adenovirus infectionInfections and infestations0/600/291/560/25
InfluenzaInfections and infestations0/600/291/560/25
Meningitis viralInfections and infestations0/600/291/560/25
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTDF (Blinded Randomized Phase)Placebo (Blinded Randomized Phase)TDF to TDF (Open-Label Phase)Placebo to TDF (Open-Label Phase)
NasopharyngitisInfections and infestations9/602/2912/561/25
Upper respiratory tract infectionInfections and infestations9/605/293/563/25
PyrexiaGeneral disorders9/602/294/560/25
PharyngitisInfections and infestations3/603/292/561/25
Alanine aminotransferase increasedInvestigations3/603/290/560/25
CoughRespiratory, thoracic and mediastinal disorders5/601/290/561/25
VomitingGastrointestinal disorders3/601/290/562/25
HeadacheNervous system disorders2/602/292/560/25
Dermatitis atopicSkin and subcutaneous tissue disorders0/602/290/560/25
Abdominal painGastrointestinal disorders3/601/291/561/25

Baseline characteristics

Safety Analysis Set: all randomized participants who received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blind phase.

Age, Continuous
Age, Continuous(years)Tenofovir Disoproxil FumaratePlaceboTotal
Mean6 ± 2.57 ± 3.26 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
Female271239
Male331750
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino602989
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
American Indian or Alaska Native000
Asian411758
Native Hawaiian or Other Pacific Islander000
Black or African American415
White151126
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
South Korea231134
Romania131023
United States14317
Taiwan202
India8513
HBV DNA
HBV DNA(log10 IU/mL)Tenofovir Disoproxil FumaratePlaceboTotal
Mean8.089 ± 0.72088.133 ± 1.25388.103 ± 0.9214
Hepatitis B Virus Surface Antigen (HBsAg)
Hepatitis B Virus Surface Antigen (HBsAg)(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
Positive602989
Negative000
Hepatitis B e antigen (HBeAg)
Hepatitis B e antigen (HBeAg)(Participants)Tenofovir Disoproxil FumaratePlaceboTotal
Positive562985
Negative404

2 further baseline measures are reported on the registry.

08

Study locations

21 sites
09

References and documents

Publications

  • (Oral Presentation) Mei-Hwei Chang, Jae Hong Park, Jorge A. Bezerra, Daniela Pacura, Sandeep Nijhawan, Byung-Ho Choe, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB). Hepatology, 2018; 68 (Suppl 1): 49A.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Aug 2017, 56 months.

Results were first posted in Sep 2018, 1 year 1 month after primary completion.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2012
First posted
Jul 27, 2012
StartActual
Dec 6, 2012
Primary completionActual
Aug 7, 2017
CompletionEst.
Jul 2027
Results first posted
Sep 19, 2018
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01651403
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 27, 2012
Start date
Dec 6, 2012
Primary completion
Aug 7, 2017
Completion
Jul 2027 (estimated)
Results posted
Sep 19, 2018
Last update
Jan 30, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion